Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 737-743

  Khoury, H ^a   Adkins, D ^a   Brown, R ^a   Trinkaus, K ^b   Vij, R ^a   Miller, G ^a   Goodnough, L T ^a   DiPersio, J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Biostatistics   (United States)

Author keywords

BMT; Hepatic toxicity; High dose steroids

Indexed keywords

BILIRUBIN; GLUCOCORTICOID; METHYLPREDNISOLONE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION;

EID: 0034073098     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702209     Document Type: Article

References (46)

1. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
2. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
3. Jones RJ, Lee KSK, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
4. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
5. Shulman HM, Fisher LB, Schoch HG et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171-1180.
6. Deleve LD. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994; 268: 1261-1265.
7. Shulman HM, Luk K, Deeg HJ et al. Induction of hepatic venocclusive disease in dogs. Am J Pathol 1987; 126: 114-125.
8. Epstein RB, Min KW, Anderson SL, Syzek L. A canine model for hepatic venocclusive disease. Transplantation 1992; 54: 12-16.
9. Geraci JP, Mariano MS, Jackson KL. Radiation hepatology of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs. Radiat Res 1992; 129: 322-332.
10. Teicher BA, Crawford GM, Holde SA et al. Glutathione monoethyl esther car selectively protect liver from high dose BCNU or cyclophosphamide. Cancer 1988; 62: 1275-1281.
11. Remberger M, Ringden O. Cytokines in veno-occlusive disease of the liver after liver transplantation. Transplant Proc 1995; 27: 3533-3534.
12. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
13. Gugliotta L, Catani L, Vianelli N et al. High plasma levels of tumor necrosis factor-α may be predictive of veno-occlusive disease in bone marrow transplantation. Blood 1994; 83: 2385-2386.
14. Tanaka J, Imamura M, Kasai M et al. Rapid analysis of tumor necrosis factor-alpha mRNA expression during venoocclusive disease of the liver after allogeneic bone marrow transplantation. Transplantation 1993; 55: 430-432.
15. Van Hinsbergh VW, Kooistra T, Van Den Berg EA et al. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473.
16. Van der Poll T, Levi M, Büller HR, van Deventer SJ et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732.
17. Salat C, Holler E, Wolf C et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184-21888.
18. Gertler JP, Abbolt WM. Prothrombotic and fibrinolytic function of normal and perturbed endothelium. J Surg Res 1992; 52: 89-95.
19. Nawroth PP, Stern DM. Endothelial cell procoagulation properties and the host response. Semin Thromb Hemost 1987; 13: 391-397.
20. Collins PW, Gutteridge CN, O'Driscoll A et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992; 10: 499-506.
21. Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 1980; 104: 584-588.
22. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-558.
23. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178-1191.
24. Heikinheimo M, Halila R, Fasth A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994; 83: 3036-3040.
25. McDonald GB. Venoocclusive disease of the liver following marrow transplantation. Marrow Transplant Rev 1994; 3: 129-134.
26. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
27. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506.
28. Almawi W, Beyhum H, Rahme A, Rieder M. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leuk Biol 1996; 60: 563-572.
29. Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioassays 1996; 18: 371-378.
30. Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
31. Attal M, Huguet F, Rubie H et al. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective randomized trial. Blood 1992; 79: 2834-2840.
32. Goyal RK, Wall DA, Yu LC. Identification of patients with hepatic venoocclusive disease likely to respond to r-tPA therapy. Blood 1993; 10: 632 (Abstr.).
33. Schriber J, Christianen N, Baer MR et al. Tissue plasminogen activator as therapy for hepatotoxicity following bone marrow transplantation. Blood 1995; 86: 220 (Abstr.).
34. Carreras E, Granena A, Navasa M et al. On the reliability of clinical criteria tor the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66: 77-80.
35. Blostein MD, Thiebeault Apaltiel OB, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Blood 1991; 78: 240 (Abstr.).
36. Matute-Bello G, McDonald GD, Hinds MS et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125-1130.
37. Miniero R, Vassallo E, Soldano S et al. Management of hepatic veno-occlusive disease in pediatric patients: retrospective analysis in six AIEOP-BMT centers. Bone Marrow Transplant 1996; 18 (Suppl. 2): 157-159.
38. Carreras E, Betz H, Arcese W et al. Incidence of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the EBMT. Blood 1998; 92: 3599-3604.
39. Richardson PG, Elias AD, Krishnan A et al. Treatment of severe VOD with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
40. Schlitt HJ, Tishler JH, Binge B et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation-clinical and immunological considerations. Bone Marrow Transplant 1995; 16: 473-478.
41. Rappaport AP, Doyle HR, Starzl T et al. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991; 8: 421-424.
42. Murray JA, LaBreque DR, Gingrich RD et al. Successful treatment of hepatic veno-occlusive disease in a bone marrow transplant patient with side-to-side portacaval shunt. Gastrenterology 1987; 92: 1073-1077.
43. Jacobson BK, Kalayoglu M. Effective early treatment of hepatic veno-occlusive disease with a central splenorenal shunt in an infant. J Pediatr Surg 1992; 27: 531-533.
44. Smith OF, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting for treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18: 643-646.
45. De la Rubia J, Carral A, Montes H et al. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt. Haematologica 1996; 81: 536-539.
46. Levy V, Azoulay D, Rio B et al. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt. Bone Marrow Transplant 1996; 18: 443-445.